Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Canada Graduate Scholarships

University of Ottawa

$105,000.00

Pushing RNA polymerase II transcription: How HDV might hold the key to new antiviral therapies

FY 2021-22

Summary
Once viruses have infected our cells, they use our cellular machinery to replicate and eventually infect new cells. But there is a catch. Transcription by our polymerase (RNAPII) is usually paused shortly after it has initiated. This pause allows gene expression to be regulated and for the newly formed transcripts to be capped, an important modification to ensure the stability of the messenger RNA (mRNA). Therefore, viruses that are transcribed by RNAPII must find a way to either get around this pause or to use it to their advantage. My project focuses on two viruses that have found ways to use this pause to their advantage: the influenza A virus (IAV) and HIV. IAV produces its own polymerase, responsible for viral transcription and replication. But while IAV does not directly use RNAPII, it still interacts with it as the viral polymerase cannot cap its mRNAs. Therefore, the viral polymerase interacts with RNAPII during its pause to steal the cap structure from its nascent mRNA in a process called cap-snatching. HIV, on the other hand, is directly transcribed by RNAPII. In actively infected cells, HIV uses one of its viral proteins (Tat) to release the pause and stimulate transcription of viral genes. However, HIV can enter latency, a state characterized by minimal viral transcription in the infected cells, leading to suboptimal levels of Tat and a longer transcriptional pause. Due to their minimal viral transcription, these latently infected cells are not detected by antiretrovirals and create viral reservoirs. My project focuses the use of a protein (HDAg-S) from the hepatitis delta virus as a mean to stimulate transcription by RNAPII. I hypothesize that using HDAg-S on IAV infected cells would lead to a reduction in cap-snatching and therefore viral transcription and replication. Also, using HDAg-S on HIV-infected individuals would stimulate transcription of latent viruses, leading to their reactivation and them finally being detected by antiretrovirals.
Program
Doctoral Research Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
458909
Name
Whelan Marilyn
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Pushing RNA polymerase II transcription: How HDV might hold the key to new antiviral therapies
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Hepatitis Delta Virus; Hiv; Influenza; Molecular Biology; Nelf; Rna Polymerase Ii; Viral Infections; Viral Reservoirs
Abstract
Once viruses have infected our cells, they use our cellular machinery to replicate and eventually infect new cells. But there is a catch. Transcription by our polymerase (RNAPII) is usually paused shortly after it has initiated. This pause allows gene expression to be regulated and for the newly formed transcripts to be capped, an important modification to ensure the stability of the messenger RNA (mRNA). Therefore, viruses that are transcribed by RNAPII must find a way to either get around this pause or to use it to their advantage. My project focuses on two viruses that have found ways to use this pause to their advantage: the influenza A virus (IAV) and HIV. IAV produces its own polymerase, responsible for viral transcription and replication. But while IAV does not directly use RNAPII, it still interacts with it as the viral polymerase cannot cap its mRNAs. Therefore, the viral polymerase interacts with RNAPII during its pause to steal the cap structure from its nascent mRNA in a process called cap-snatching. HIV, on the other hand, is directly transcribed by RNAPII. In actively infected cells, HIV uses one of its viral proteins (Tat) to release the pause and stimulate transcription of viral genes. However, HIV can enter latency, a state characterized by minimal viral transcription in the infected cells, leading to suboptimal levels of Tat and a longer transcriptional pause. Due to their minimal viral transcription, these latently infected cells are not detected by antiretrovirals and create viral reservoirs. My project focuses the use of a protein (HDAg-S) from the hepatitis delta virus as a mean to stimulate transcription by RNAPII. I hypothesize that using HDAg-S on IAV infected cells would lead to a reduction in cap-snatching and therefore viral transcription and replication. Also, using HDAg-S on HIV-infected individuals would stimulate transcription of latent viruses, leading to their reactivation and them finally being detected by antiretrovirals.
Competitiondate
202111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Whelan, Marilyn
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~